<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146717">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190475</url>
  </required_header>
  <id_info>
    <org_study_id>CBGS649A2105</org_study_id>
    <nct_id>NCT01190475</nct_id>
  </id_info>
  <brief_title>BGS649 Monotherapy in Moderate to Severe Endometriosis Patients</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Placebo-controlled Study of Oral BGS649 Monotherapy Assessing Safety and Tolerability in Patients With Moderate to Severe Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of BGS649 in women with moderate to
      severe endometriosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: To evaluate the safety &amp; tolerability of multiple dosing of BGS649 at two dose levels over 53 months in pre-menopausal women with moderate-severe endometriosis, as assessed by serial transvaginal ultrasonography &amp; bone resorption biomarker</measure>
    <time_frame>8 months. Evaluate safety and tolerability from baseline up to 3 months of treatment via transvaginal ultrasonography and up to 5 months from baseline to month 5 via bone resorption biomarker.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure: To evaluate the pharmacokinetic profile of BGS649 following multiple dosing at two dose levels over 3 months in pre-menopausal women with moderate to severe endometriosis.</measure>
    <time_frame>8 months (Assess PK profile from first dosing through end of study and compare PK on Day 1 of first dose to that of third month)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>BGS649 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BGS649 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGS649</intervention_name>
    <arm_group_label>BGS649 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGS649</intervention_name>
    <arm_group_label>BGS649 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women with documented moderate to severe endometriosis. Occurrence of
             three sequential menstrual cycles of 24-35 days duration prior to enrollment.

          -  Laparoscopically proven diagnosis of moderate to severe endometriosis (diagnosed
             within the past 10 years before screening).

          -  Patients not planning to become pregnant within one year after the screening visit
             and willing to use two effective methods of non-hormonal, barrier birth control for
             the duration of the study or who are surgically sterile.

          -  Patients must have a score of at least 4 on the numerical rating scale (NRS) for one
             of the following three pain measurements: pelvic pain, menstrual pain and dyspareunia

        Exclusion Criteria:

          -  Estrogen replacement therapy using either prescription medications or
             estrogen-containing OTC nutritional/herbal supplements such as soy extracts or
             topical estrogens.

          -  Aromatase inhibitor therapy (includes Femara (letrozole), Aromasin (exemestane) or
             Arimidex (anastrozole) within the past 12 months.

          -  Oral bisphosphonate therapy (i.e. Fosamax (alendronate)) within the past 6 months or
             intravenous bisphosphonate (i.e., Reclast, pamidronate) &lt; 15 months from screening.

          -  Systemic glucocorticoid therapy within the past 4 weeks.

          -  Contra-indications to oral contraceptive use.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 10, 2012</lastchanged_date>
  <firstreceived_date>August 19, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>July 31, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>Infertility</keyword>
  <keyword>Pain</keyword>
  <keyword>Vaginal Diseases</keyword>
  <keyword>Uterine Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
